Clinical Trial Update: Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for omiganan BID in facial seborrheic dermatitis; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seborrheic Dermatitis

Drugs mentioned

• Omiganan (omiganan)

Snippet

Sponsor: Maruho Co., Ltd. | Conditions: Seborrheic Dermatitis | Phase 2 | Status: UNKNOWN